Takeda

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancer, hepatitis B virus (HBV), and age-related diseases. Founded in 2009 and headquartered in Suzhou, China, the company has established a diverse pipeline of drug candidates, including HQP1351, a BCR-ABL/KIT inhibitor targeting resistant mutations, and APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies. Additional candidates include APG-1252, aimed at restoring apoptosis in various solid tumors, and APG-115, which targets the MDM2-p53 interaction in solid tumors and lymphoma. Ascentage Pharma also develops APG-1387 for advanced solid tumors and chronic HBV infection, alongside other therapies for non-small-cell lung carcinoma and chronic lymphocytic leukemia. The company has entered into clinical collaborations to explore innovative treatment combinations, furthering its commitment to addressing challenging diseases in the oncology landscape.

Maia Oncology is a virtual onco-primary care clinic that focuses on providing comprehensive care for cancer patients and survivors. The clinic operates a platform designed to coordinate cancer care, tracking important patient outcomes such as hospitalizations, emergency room visits, and the emergence of new comorbidities. This approach helps patients manage the complexities and long-term effects associated with cancer treatment. By offering a supportive environment, Maia Oncology aims to enhance the navigation of treatment-related challenges and improve overall patient well-being.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at improving cancer treatment outcomes. The company focuses on addressing how tumors manipulate the immune system, creating therapies tailored for specific molecularly defined patient groups. By targeting the critical interactions between tumors and the immune system, Larkspur's approach seeks to enhance patients' immune responses, particularly in colorectal cancer and other malignancies. This strategic focus aims to overcome existing challenges that allow tumors to evade immune detection and attack, thereby advancing the efficacy of cancer therapies.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Nimbus Lakshmi operates as a wholly-owned subsidiary of Nimbus Therapeutics and offers tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858, an orally administered, selective allosteric inhibitor of TYK2, is currently undergoing assessment for its potential in treating various autoimmune diseases, following promising Phase 2b outcomes in psoriasis.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Adaptate Biotherapeutics is a biotherapeutics company based in London, founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technology, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. The company's work holds the promise of significantly enhancing treatment options for patients, providing effective medical solutions for various immune-related conditions.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.

Adaptate Biotherapeutics is a biotherapeutics company based in London, founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technology, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. The company's work holds the promise of significantly enhancing treatment options for patients, providing effective medical solutions for various immune-related conditions.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.

Bridge Medicines LLC is a biotechnology company based in New York, established in 2016. It specializes in drug discovery and the development of innovative therapeutics for various human diseases, particularly in oncology and rare diseases. The company collaborates with prominent institutions such as Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine, as well as industry partners like Takeda Pharmaceutical Company. Bridge Medicines focuses on advancing technologies from academic research through to clinical development, with a notable emphasis on developing inhibitors for acute leukemias and small molecule inhibitors for hereditary angioedema and inflammatory disorders. The initiative aims to provide comprehensive support throughout the drug development process, from validating preclinical studies to advancing candidates into human clinical trials.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Palleon Pharmaceuticals is a biotechnology company that develops therapeutics targeting glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in creating glycoimmune checkpoint inhibitors, a novel class of drugs designed to enhance immune response against cancer. By integrating insights from global leaders in glycoscience and human immunology, Palleon aims to provide a broader array of combination therapies that not only address cancer but also combat resistance to traditional immuno-oncology treatments. Additionally, the company develops therapies for inflammatory diseases, including autoimmunity and fibrosis.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company is dedicated to discovering and developing transformative therapies for severe liver diseases. Ambys focuses on creating innovative gene, drug, and cell therapies aimed at restoring liver function, halting the progression of liver disease, and addressing the complications associated with liver failure. By leveraging regenerative and restorative medical approaches, Ambys Medicines seeks to improve the lives of individuals affected by chronic liver conditions, providing potential relief through advanced therapeutic options.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company is dedicated to discovering and developing transformative therapies for severe liver diseases. Ambys focuses on creating innovative gene, drug, and cell therapies aimed at restoring liver function, halting the progression of liver disease, and addressing the complications associated with liver failure. By leveraging regenerative and restorative medical approaches, Ambys Medicines seeks to improve the lives of individuals affected by chronic liver conditions, providing potential relief through advanced therapeutic options.

Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.

ARTham Therapeutics Inc. is a biopharmaceutical company based in Naka-Ku, Japan, founded in 2018. The company is focused on developing innovative, disease-modifying medicines aimed at improving patient health. It offers a range of programs, including art-648, art-ep, art-pde, and art-001, targeting conditions such as inflammatory skin diseases, vascular malformations, and immuno-oncology endometriosis. ARTham operates a virtual research and development model that fosters collaboration with academic and business partners to drive innovation in drug development. Through its efforts, ARTham Therapeutics seeks to address specific medical needs, enhance patient recovery, and improve overall quality of life.

Reborna Biosciences Inc focuses on research and development in the field of genetic diseases, specifically targeting unmet medical needs associated with rare genetic disorders. Based in Fujisawa, Japan, the company develops therapeutic options that utilize a unique technology enabling low-molecular compounds to effectively target ribonucleic acid (RNA). This innovative approach facilitates the creation of disease-modifying drugs aimed at treating conditions such as spinal muscular atrophy and other rare genetic diseases. By leveraging the natural three-dimensional structure of RNA, Reborna Biosciences aims to normalize RNA function and improve treatment outcomes for patients suffering from these challenging conditions.

Quince Therapeutics is a preclinical stage biopharmaceutical company focused on developing innovative precision therapeutics aimed at treating debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or larger compounds directly to the site of bone fractures and related diseases. This targeted approach is designed to promote faster healing while minimizing off-target safety concerns commonly associated with traditional therapies. By concentrating on the specific needs of patients suffering from impairment of strength, functionality, or debilitating conditions, Quince Therapeutics aims to provide effective treatments that enhance patient outcomes.

Shire is a prominent biotechnology company headquartered in Ireland, dedicated to addressing the needs of individuals with rare diseases. With a strong global presence, it operates in key markets including the United States, Canada, the UK, and several major European countries. Shire's product portfolio is diverse, encompassing therapies for genetic diseases, neuroscience, internal medicine, hematology, immunology, and oncology. The company has expanded significantly through strategic mergers and acquisitions, such as the purchase of Transkaryotic Therapies, ViroPharma, NPS Pharma, Baxalta, and Dyax, which have bolstered its capabilities in various therapeutic areas. Shire emphasizes a patient-centered culture that fosters innovation, accountability, and ethical practices, aiming to enhance the quality of life for patients with life-altering conditions. The organization prioritizes employee development within a collaborative environment, enabling quick decision-making and adaptability in its operations.

Fimecs is a biotechnology firm specializing in drug discovery through protein degradation technology. The company focuses on developing innovative therapeutics aimed at treating cancers and other challenging diseases. Fimecs utilizes a drug discovery platform that operates on a ubiquitin E3 ligase binder, which facilitates the design of small molecules that induce the degradation of specific, disease-related proteins. While the human body contains over 18,000 proteins, approximately 1,500 are linked to various diseases, yet only around 300 have been identified as viable targets for small molecule drug interventions. Fimecs aims to expand the possibilities of druggable targets by addressing these previously undruggable proteins, ultimately seeking to enhance treatment options for patients.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Outpost Medicine, founded in 2016 and based in the United States, focuses on developing innovative therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to addressing gastrointestinal and urologic conditions, with its lead clinical-stage product candidate, OP-233, aimed at treating stress urinary incontinence (SUI), a condition characterized by involuntary urine loss during physical activities. Additionally, Outpost is working on treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS), reflecting its commitment to advancing healthcare solutions in these areas.

Palleon Pharmaceuticals is a biotechnology company that develops therapeutics targeting glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in creating glycoimmune checkpoint inhibitors, a novel class of drugs designed to enhance immune response against cancer. By integrating insights from global leaders in glycoscience and human immunology, Palleon aims to provide a broader array of combination therapies that not only address cancer but also combat resistance to traditional immuno-oncology treatments. Additionally, the company develops therapies for inflammatory diseases, including autoimmunity and fibrosis.

Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.

Quince Therapeutics is a preclinical stage biopharmaceutical company focused on developing innovative precision therapeutics aimed at treating debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or larger compounds directly to the site of bone fractures and related diseases. This targeted approach is designed to promote faster healing while minimizing off-target safety concerns commonly associated with traditional therapies. By concentrating on the specific needs of patients suffering from impairment of strength, functionality, or debilitating conditions, Quince Therapeutics aims to provide effective treatments that enhance patient outcomes.

Scohia Pharma, Inc. is a biotechnology company based in Fujisawa, Japan, that specializes in researching, designing, and developing therapeutic drugs for metabolic, cardiovascular, and renal diseases. Established in 2017, the company focuses on addressing conditions such as obesity, diabetes, dyslipidemia, and hypertension through its innovative pipeline of drug development programs. Scohia Pharma aims to enhance patient quality of life by providing new treatment options for patients and healthcare professionals, leveraging its substantial research and development capabilities while maintaining the agility to make swift decisions in the evolving pharmaceutical landscape.

Ariad Pharmaceuticals, based in Cambridge, Massachusetts, is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of innovative cancer treatments. The company is known for its drug Iclusig (ponatinib), a tyrosine kinase inhibitor approved for adult patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Additionally, Ariad is developing Brigatinib, aimed at treating non-small cell lung cancer, and AP32788, which targets non-small cell lung cancer and other solid tumors. Iclusig is marketed through specialty pharmacies in the United States. Ariad also has licensing agreements with Medinol Ltd. to develop medical devices related to its drug ridaforolimus. Founded in 1991, Ariad Pharmaceuticals operates as a subsidiary of Takeda Pharmaceuticals U.S.A., Inc. as of February 2017.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

Bridge Medicines LLC is a biotechnology company based in New York, established in 2016. It specializes in drug discovery and the development of innovative therapeutics for various human diseases, particularly in oncology and rare diseases. The company collaborates with prominent institutions such as Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine, as well as industry partners like Takeda Pharmaceutical Company. Bridge Medicines focuses on advancing technologies from academic research through to clinical development, with a notable emphasis on developing inhibitors for acute leukemias and small molecule inhibitors for hereditary angioedema and inflammatory disorders. The initiative aims to provide comprehensive support throughout the drug development process, from validating preclinical studies to advancing candidates into human clinical trials.

Bioniz Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative peptide therapeutics aimed at treating immune diseases and cancer. Founded in 2009 and based in Irvine, California, Bioniz has a pipeline that includes BNZ-1, a selective inhibitor of interleukin cytokines IL-2, IL-9, and IL-15, which are significant contributors to conditions such as HTLV-1 Associated Myelopathy and T-cell leukemias. The company is also developing IL-15 and IL-21 inhibitors, along with BNZ-3, an early-stage asset targeting IL-4, IL-9, and IL-21 cytokines. Bioniz Therapeutics aims to complete proof of concept and preclinical studies for its lead technologies while seeking partnerships for clinical trials and commercialization, reflecting its commitment to enhancing global public health through novel therapeutic solutions.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Outpost Medicine, founded in 2016 and based in the United States, focuses on developing innovative therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to addressing gastrointestinal and urologic conditions, with its lead clinical-stage product candidate, OP-233, aimed at treating stress urinary incontinence (SUI), a condition characterized by involuntary urine loss during physical activities. Additionally, Outpost is working on treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS), reflecting its commitment to advancing healthcare solutions in these areas.

Quince Therapeutics is a preclinical stage biopharmaceutical company focused on developing innovative precision therapeutics aimed at treating debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or larger compounds directly to the site of bone fractures and related diseases. This targeted approach is designed to promote faster healing while minimizing off-target safety concerns commonly associated with traditional therapies. By concentrating on the specific needs of patients suffering from impairment of strength, functionality, or debilitating conditions, Quince Therapeutics aims to provide effective treatments that enhance patient outcomes.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. It specializes in developing novel small-molecule antiviral therapeutics using an innovative drug discovery platform that employs cell-free protein synthesizing systems. This approach allows for the identification of active compounds that may be overlooked by traditional pharmaceutical screening methods. Prosetta's research addresses a broad range of human diseases, including oncology, neurodegenerative disorders, and infectious diseases, and the company collaborates with both commercial partners and non-profit organizations to advance its compounds. Through its efforts, Prosetta Biosciences aims to enable healthcare professionals to discover and utilize small molecules that effectively modulate the assembly of multi-protein complexes within cells.

Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation, and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines. BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally. The company was founded in 2012 and is headquartered in Cleveland, Ohio.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract. Their novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. There has been an explosion of interest in foods that have additional physiological benefits. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the GI mucosal interface harnessing recent technological developments, including analysis of the microbiota and advances in mucosal immunology. Conventional antibodies are degraded in the gut and therefore efficacy obtained from oral administration is limited. VHsquared uses domain antibodies that can be selected and engineered to resist degradation, are intrinsically very stable and are locally active in the gastrointestinal tract. Products will offer advantages in terms of specificity, safety, efficacy, convenience and cost.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

ArmaGen, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapies for severe neurological diseases, particularly lysosomal storage disorders. The company's product pipeline includes AGT-182, aimed at treating Hunter syndrome, and AGT-181, designed for Hurler syndrome. ArmaGen's innovative therapies are engineered to penetrate the blood-brain barrier, addressing neurological complications associated with various conditions, including neurodegenerative diseases like Alzheimer’s and Parkinson’s. Founded in 2001, ArmaGen aims to enhance treatment options for patients suffering from these challenging disorders.

Envoy Therapeutics focuses on drug discovery with the aim of developing new medications that demonstrate improved efficacy and reduced side effects compared to existing treatments. Utilizing its innovative bacTRAP® technology, the company identifies proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This capability is particularly significant in brain tissues, where numerous cell types are closely intermingled. By allowing for the targeted modulation of specific cell types based on their unique protein expression, Envoy Therapeutics enhances the possibilities for therapeutic interventions, marking a significant advancement in the field of drug discovery.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, specializing in contract research and contract manufacturing services focused on drug discovery. Established in 2001, the company offers a comprehensive range of services including medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex also employs advanced technologies for hit identification and combinatorial domain hunting. The company is particularly noted for its work in developing innovative treatments for inflammatory diseases, such as DMXD-011, a small-molecule inhibitor targeting TBK1/IKKε/SIK2 for conditions like rheumatoid arthritis and lupus. Through its capabilities in biology and chemistry, Domainex aims to assist healthcare professionals in addressing complex drug discovery challenges, particularly in oncology and related fields.

Envoy Therapeutics focuses on drug discovery with the aim of developing new medications that demonstrate improved efficacy and reduced side effects compared to existing treatments. Utilizing its innovative bacTRAP® technology, the company identifies proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This capability is particularly significant in brain tissues, where numerous cell types are closely intermingled. By allowing for the targeted modulation of specific cell types based on their unique protein expression, Envoy Therapeutics enhances the possibilities for therapeutic interventions, marking a significant advancement in the field of drug discovery.

IDM Pharma is a biopharmaceutical company dedicated to developing innovative treatments for cancer. The company focuses on products that either eliminate cancer cells by activating the immune system or prevent tumor recurrence by inducing a specific adaptive immune response. IDM Pharma aims to enhance the therapeutic and commercial potential of its offerings to meet the needs of both patients and healthcare providers. Through its research and development efforts, the company seeks to control cancer effectively while maintaining the quality of life for those affected.

Millennium Pharmaceuticals is a biopharmaceutical company that engages in the research, development, and commercialization of medicines for the treatment of cancer in the United States and internationally. It develops and markets VELCADE for injection, a cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts with facilities in San Diego, San Francisco, Tsukuba, and Osaka. As of May 13, 2008, Millennium Pharmaceuticals, Inc. operates as a subsidiary of Takeda Pharmaceutical Co. Ltd.

Takeda Bio Development Center Limited engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. Takeda Bio Development Center Ltd. was formerly known as Amgen Kabushiki Kaisha. As a result of the acquisition of Amgen Kabushiki Kaisha by Takeda Pharmaceutical Co., Amgen Kabushiki Kaisha's name was changed. As of April 1, 2008, Takeda Bio Development Center Ltd. operates as a subsidiary of Takeda Pharmaceutical Co. Ltd.

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates aimed at treating epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, Xenon is developing XEN007, a central nervous system-acting calcium channel modulator, also in Phase I trials. The company leverages insights from genetic research, particularly from families with severe phenotypes, to identify drug targets, which may extend beyond rare genetic disorders. Furthermore, Xenon has established a collaboration with Neurocrine Biosciences to advance the development of innovative epilepsy treatments.

Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.

Syrrx Inc focuses on drug targets that have been validated in human clinical trials and directs its efforts toward therapeutics to treat metabolic diseases, cancer, and inflammation. Syrrx exploits its competitive advantage in high-throughput structural biology to be the first organization to determine the three dimensional structure of known drug targets. Syrrx then uses these structures to drive iterative, structure-based drug design programs to efficiently generate potential drug candidates. Syrrx has an ongoing partnership for the development and commercialization of Syrrx-designed human dipeptidyl peptidase IV (DPP IV) inhibitors as drug products for the treatment of type 2 diabetes and other major human diseases. Syrrx also has a strategic alliance for the discovery and early development of inhibitors targeting human HDACs and HSD1.

BioNumerik Pharmaceuticals, Inc. is dedicated to the discovery, development, and commercialization of pharmaceutical agents for cancer treatment and supportive care. Founded in 1992 and based in San Antonio, Texas, the company focuses on innovative drug candidates such as Tavocept, which targets both oncology and non-oncology indications, and Karenitecin, a new anti-tumor drug within the camptothecin class of chemotherapy. Additionally, BioNumerik is engaged in various oncology research programs, including preclinical development of DNA methyltransferase modulators, novel platinum drugs, small molecule Bcl-2 inhibitors, and formulations aimed at reducing neuro and nephro-toxicity. The company employs a multidisciplinary technology platform that integrates chemistry, biology, and advanced computational methods to enhance drug discovery and development processes.

Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.